[{"id":"b88cc8bc-838d-43e3-8862-07db1c3a612f","acronym":"SWOG-S1318","url":"https://clinicaltrials.gov/study/NCT02143414","created_at":"2021-01-18T09:57:21.812Z","updated_at":"2025-02-25T16:36:22.860Z","phase":"Phase 2","brief_title":"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02143414 - SWOG-S1318","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R","pipe":" | ","alterations":" ABL2 fusion","tags":["ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • mercaptopurine delayed release (DR6MP) • mercaptopurine • Xatmep (methotrexate oral solution)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/30/2015","start_date":" 06/30/2015","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 10/23/2025","study_completion_date":" 10/23/2025","last_update_posted":"2025-02-06"},{"id":"63d27786-955f-456f-9b97-5a7e4032fa84","acronym":"","url":"https://clinicaltrials.gov/study/NCT00267865","created_at":"2021-01-18T00:54:41.110Z","updated_at":"2024-07-02T16:36:44.616Z","phase":"Phase 2","brief_title":"Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma","source_id_and_acronym":"NCT00267865","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • methotrexate • leucovorin calcium • Xatmep (methotrexate oral solution) • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 09/14/2006","start_date":" 09/14/2006","primary_txt":" Primary completion: 09/18/2019","primary_completion_date":" 09/18/2019","study_txt":" Completion: 09/19/2019","study_completion_date":" 09/19/2019","last_update_posted":"2020-06-01"},{"id":"407ac7e6-0c0a-45e1-bb71-0bd4c56bdc2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01848457","created_at":"2021-01-18T08:14:55.358Z","updated_at":"2024-07-02T16:36:48.338Z","phase":"Phase 2","brief_title":"Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy","source_id_and_acronym":"NCT01848457","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" KIM1","pipe":"","alterations":" ","tags":["KIM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xatmep (methotrexate oral solution) • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 01/04/2016","primary_completion_date":" 01/04/2016","study_txt":" Completion: 10/01/2016","study_completion_date":" 10/01/2016","last_update_posted":"2020-03-16"}]